Project

A phase I study of Inotuzumab Ozogamicin (CMC-544) in combination with Temsirolimus (CCI-779) in patients with relapsed or refractory CD22-positive B-cell Non Hodgkin’s Lymphomas

Automatically Closed · 2012 until 2013

RSS